The historical rank and industry rank for BeOne Medicines's Operating Margin % or its related term are showing as below:
MEX:BGNEN'
s Operating Margin % Range Over the Past 10 Years
Min: -10940.19 Med: -124.36 Max: 11.95
Current: 11.95
MEX:BGNEN's Operating Margin % is ranked better than 83.07% of 945
companies
in the Biotechnology industry
Industry Median: -86.89
vs MEX:BGNEN: 11.95
BeOne Medicines's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
BeOne Medicines's Operating Income for the
three
months ended in Mar. 2026 was MXN4,506 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was MXN12,485 Mil.
Warning Sign:
BeOne Medicines Ltd had lost money in 58% of the time over the past 12quarters.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
BeOne Medicines Operating Margin % Related Terms
BeOne Medicines Operating Margin % Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BGNEN vs RVMD, RPRX, BNTX: Operating Margin % Comparison
For the Biotechnology subindustry, BeOne Medicines's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Operating Margin % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BeOne Medicines's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (MEX:BGNEN) has a Operating Margin % of 16.51% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #160 out of 945 companies in the Biotechnology industry, placing it in the top 16.9%.
Is BeOne Medicines' Operating Margin % too high?
BeOne Medicines' current Operating Margin % is 16.51%. Based on the distribution chart, BeOne Medicines ranks #160 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Operating Margin % compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #160 out of 945 companies for Operating Margin %. This places BeOne Medicines in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Operating Margin % is 16.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Operating Margin % of 16.51%. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Operating Margin % is 16.51%. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Operating Margin % is 16.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
Operating Margin %: 16.51%
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
